...
MISTMICRO

Milestone Pharmaceuticals Inc.

HealthcareBiotechnology
$1.71
$0.00(-0.58%)
52W$0.63
$3.06
FinancialsValuationvs UTHR
Updated Mar 2, 12:00 AM
RSI40
RS Rating35/99
Beta1.32
Volatility106%
F-Score2/9
Mkt Cap$146M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Milestone Pharmaceuticals Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 35), showing significant lag compared to the market leaders. Earnings growth of 14% provides fundamental context to the price action. Investors should exercise caution due to high volatility (106% annualized), which requires wider risk management.

Relative Strength
35
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.32
vs S&P 500
ABOVE MKT
52W Position
45%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$1.92
50 SMA > 100 SMA$2.05
100 SMA > 150 SMA$1.96
150 SMA > 200 SMA$1.89

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$1.77-3.40%BELOW
50 SMA$1.92-11.15%BELOW
100 SMA$2.05-16.62%BELOW
150 SMA$1.96-12.72%BELOW
200 SMA$1.89-9.50%BELOW

Price Performance

1D-0.6%
1W+1.2%
1M-11.9%
3M-36.4%
6M-5.5%
YTD-16.6%
1Y+4.9%
3Y-18.5%
52-Week Trading Range45% from low
$1.71
52W Low$0.63
52W High$3.06

Technical Indicators

RSI (14)BEARISH
39.6
305070
VCP ScoreCOOL
5/10
Base depth: 84.8%

Risk Profile

Beta
1.32
52W Vol
106%
ATR
$0.08
Max DD (1Y)
-73%

Volume Analysis

Today
1
50D Avg
2.55M
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+51%
$-0.20
Q1'25-48%
$-0.31
Q2'25-43%
$-0.20
Q3'25+14%
$-0.12
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:—

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+7.78%

Stock Price CAGR

10 Years:-19.72%
5 Years:-25.62%
3 Years:-18.51%
1 Year:+4.91%

Return on Equity

10Y Avg:-123.9%
5Y Avg:-111.7%
3Y Avg:-162.1%
Last Year:-283.0%

Key Metrics

Market Cap$146M
Gross Margin—
Net Margin—
Piotroski F-Score2/9

More MIST Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

MIST vs UTHRUTHRZLABAMRNALKS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 35 meansMIST outperformed 35% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.32 means 32% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is MIST in an uptrend right now?

MIST has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is MIST overbought or oversold?

MIST's RSI (14) is 40. The stock is in neutral territory, neither overbought nor oversold.

Is MIST outperforming the market?

MIST has a Relative Strength (RS) Rating of 35 out of 99. MIST is currently lagging the broader market.

Where is MIST in its 52-week range?

MIST is trading at $1.71, which is 56% of its 52-week high ($3.06) and 45% above its 52-week low ($0.63).

How volatile is MIST?

MIST has a Beta of 1.32 and 52-week volatility of 106%. It's more volatile than the S&P 500 - expect bigger swings.